NIA Psych-AD Program
PsychAD Consortium
Understanding the molecular mechanisms that contribute to neuropsychiatric symptoms in Alzheimer’s disease.
Supported by NIA grant R01AG067025
Goal of the Project
A single-cell view of the molecular complexity of brain disease
The PsychAD Consortium seeks to deepen our understanding of neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD), related dementias (ADRD), and serious mental illnesses (SMIs) by exploring shared and distinct biological pathways underlying these disorders. By combining epidemiological data with advanced multi-omic and systems biology approaches, PsychAD aims to uncover biomarkers and therapeutic targets that can improve diagnosis, prognosis, and treatment of NPS.
Using a large autopsy dataset, the consortium builds high-resolution, single-cell models to examine gene expression across genetic, developmental, and disease-related dimensions. These models reveal cell-specific pathways that influence NPS and disease progression, offering valuable insights for precision medicine. Ultimately, PsychAD strives to create a foundational framework for targeted, cross-disorder treatments that address the molecular complexity of AD, ADRD, and SMIs.
Explore
Dive into the consortium
Research
A package of 12 companion studies spanning aging, disease, genetic regulation, and computational methods.
View publications →Data
Open-access single-cell, spatial, and genomic data via the AD Knowledge Portal, CELLxGENE, and Zenodo.
Access the data →People
The consortium network of investigators and contributors across leading research institutions.
Meet the team →Grants
Funding from the National Institute on Aging supporting PsychAD’s mission.
See funding →